Dr. Eric Yu joined Matrix Partners China in 2014 focusing on broad healthcare sector, such as Biotech, Medical Devices & Diagnostics, and Digital Health. Dr. Yu’s investment cases at Matrix Partners China include: Ambrx Biopharma (NYSE: AMAM), RemeGen (HK: 9995), Peijia Medical (HK: 9996), InventisBio (SH:688382), Chemclin (SH: 688468), Belief Biomed, Bota Bio, Qihan Biotech, Beijing Biostar Pharmaceuticals, Genecast, Advaccine, etc.

Prior to joining Matrix Partners China, Dr. Yu was responsible for healthcare investments at Fidelity Growth Partners China from 2012 to 2014. From 2009 to 2012, Dr. Yu served as the Deputy General Manager of the Northeast office of Shenzhen Capital Group, where he helped found the branch and was responsible for developing investment opportunities in the region. Prior to this, Dr. Yu worked in the Global Healthcare Department of UBS Investment Bank and McKinsey’s New York office. Dr. Yu has also conducted research in bioinformatics and structured drug design at Yale University and Columbia University, respectively.

In 2021, Dr. Yu was rated by 36Kr as China’s TOP20 Investors in Healthcare.